With President-elect Donald J. Trump officially moving into the White House, manufacturing business leaders have quickly laid out their top priorities for his administration, eager to see substantial changes that will benefit their industry. Among the most prominent of these priorities is the
The global biopharma supply chain is on the brink of a significant shift, driven by legislative changes and economic pressures. The BIOSECURE Act and the Inflation Reduction Act (IRA) are poised to reshape the landscape and create new opportunities for India's Contract Development and
In light of potential regulatory relaxations under the Trump administration, South Korean pharmaceutical and biotech companies are eagerly eyeing the opportunities to secure FDA approvals for their innovative drugs. This ambitious pursuit has been catalyzed by the prospect of a more lenient
The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has
The global C-arms market is on the cusp of significant transformation, driven by technological advancements and evolving healthcare needs. Valued at $2.21 billion in 2023, the market is projected to reach $2.35 billion in 2024, continuing its growth trajectory. This article delves into the key
In the quest for a sustainable future, the bioeconomy emerges as a significant solution, aiming to replace finite petrochemical resources with renewable resources produced by living organisms. This vision is driven by the need to create a circular economy where products and materials are fully
